Nexaver

Nexaver

SCHEMBL14680554

[2H]C([2H])([2H])CC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1

nearest known ligand 0.74

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAF1 P04049 9/20 0.74
KDR P35968 7/20 0.74
RET P07949 3/20 0.74
BRAF P15056 3/20 0.74
PDGFRB P09619 3/20 0.74
GSK3B P49841 2/20 0.74
RIPK2 O43353 2/20 0.74
ABCB11 O95342 2/20 0.74
ABL1 P00519 2/20 0.74
HTR1A P08908 2/20 0.74
ADORA3 P0DMS8 2/20 0.74
KIT P10721 2/20 0.74
FGFR1 P11362 2/20 0.74
PDGFRA P16234 2/20 0.74
FLT1 P17948 2/20 0.74
MAOA P21397 2/20 0.74
EPHA1 P21709 2/20 0.74
TBXA2R P21731 2/20 0.74
EPHA2 P29317 2/20 0.74
TTK P33981 2/20 0.74

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Nexaver SCHEMBL13004783 0.94 RAF1 (0.80) RAF1KDRRETBRAFPDGFRB
SCHEMBL8167091 0.88 RAF1 (0.78) RAF1KDRRETBRAFPDGFRB
SCHEMBL10000735 0.88 RAF1 (0.83) RAF1KDRRETBRAFPDGFRB
Sorafenib SCHEMBL14481281 0.87 RAF1 (0.89) RAF1KDRRETBRAFPDGFRB
SCHEMBL14481192 0.87 RAF1 (0.81) RAF1KDRRETBRAFPDGFRB
Sorafenib SCHEMBL14481164 0.86 RAF1 (0.88) RAF1KDRRETBRAFPDGFRB
Cm-4307 SCHEMBL30172564 0.86 RAF1 (0.88) RAF1KDRRETBRAFPDGFRB
Cm-4307 SCHEMBL14480690 0.86 RAF1 (0.88) RAF1KDRRETBRAFPDGFRB
Cm-4307 SCHEMBL29362075 0.86 RAF1 (0.88) RAF1KDRRETBRAFPDGFRB
SCHEMBL3407209 0.86 RAF1 (0.80) RAF1KDRRETBRAFPDGFRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8669369-B2 Method and process for preparation and production of deuterated Ω-diphenylurea SUZHOU ZELGEN BIOPHARMACEUTICAL CO., LTD. (CN) 2014-03-11 US disclosed
US-20130035492-A1 METHOD AND PROCESS FOR PREPARATION AND PRODUCTION OF DEUTERATED OMEGA-DIPHENYLUREA SUZHOU ZELGEN BIOPHARMACEUTICAL CO., LTD. 2013-02-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130035492-A1 METHOD AND PROCESS FOR PREPARATION AND PRODUCTION OF DEUTERATED OMEGA-DIPHENYLUREA PNLIP, PDXK, PNP RAF1 1962/4885KDR 3367/4885RET 3120/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.